Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model
Systems pharmacology:Predicting efficacy of novel anti-cancer drugs in colorectal cancer While cancer drug development relies on experimental tumor models for testing, results observed in these systems often fail to translate clinically. Kirouac et al. demonstrate how computational systems modelling...
Saved in:
Main Authors: | Daniel C. Kirouac, Gabriele Schaefer, Jocelyn Chan, Mark Merchant, Christine Orr, Shih-Min A. Huang, John Moffat, Lichuan Liu, Kapil Gadkar, Saroja Ramanujan |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/6bfc02d0615b4d33ac88a7be2e3e419b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
by: Shujun Han, et al.
Published: (2018) -
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
by: Rengyun Liu, et al.
Published: (2018) -
Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
by: Shujun Han, et al.
Published: (2018) -
Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
by: Keita Tanaka, et al.
Published: (2021) -
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
by: Maurício Fernando Silva Almeida Ribeiro, et al.
Published: (2021)